A Phase III/IV Randomized Open-Label Two Cohort Trial to Evaluate irAEs with Different Standard of Care Dosing Strategies of Pembrolizumab or Nivolumab

Brief Summary

Type:
Multiple Sites (Solid Tumors)

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT07174453

Study #:
STUDY00161901

Start Date:
Oct 07, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT07174453

View Complete Trial Details & Eligibility at ClinicalTrials.gov